Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
22,832
Total Claims
$2.1M
Drug Cost
375
Beneficiaries
$5,689
Cost/Patient
Risk Score Breakdown 22/100
Score components are additive. Read full methodology
Peer Comparison vs. 1,825 Geriatric Medicine providers
-73%
Opioid rate vs peers
0.7% vs 2.6% avg
+360%
Cost per patient vs peers
$5,689 vs $1,237 avg
+81%
Brand preference vs peers
16.6% vs 9.2% avg
⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
0.7%
Opioid Rate
157
Opioid Claims
$2,105
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 3,770 claims · $1.8M
Generic: 18,914 claims · $353K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Lipase/Protease/Amylase | 335 | $293K |
| Linaclotide | 428 | $244K |
| Icosapent Ethyl | 426 | $157K |
| Apixaban | 192 | $132K |
| Sitagliptin Phosphate | 160 | $103K |
| Linagliptin | 150 | $93K |
| Dulaglutide | 85 | $85K |
| Dapagliflozin Propanediol | 117 | $75K |
| Rivaroxaban | 69 | $42K |
| Fluticasone Propion/Salmeterol | 85 | $40K |
| Fluticasone/Vilanterol | 92 | $39K |
| Memantine Hcl/Donepezil Hcl | 60 | $39K |
| Dexlansoprazole | 140 | $35K |
| Vortioxetine Hydrobromide | 60 | $30K |
| Budesonide/Formoterol Fumarate | 62 | $30K |
Prescribing Profile
Patient Profile
81
Avg Age
71%
Female
1.95
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data